Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 9/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.40 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18113197 | 0.92 | MAPK1 (0.53) | MAPK1GRM5MAPKAPK2GSK3BPARP10 | |
| SCHEMBL18113021 | 0.83 | MAPK1 (0.50) | MAPK1GRM5MAPKAPK2PARP10PARP11 | |
| SCHEMBL18113027 | 0.83 | MAPK1 (0.53) | MAPK1GRM5MAPKAPK2PARP10PARP11 | |
| SCHEMBL18113048 | 0.82 | MAPK1 (0.51) | MAPK1MAPKAPK2PARP10PARP11TGFBR1 | |
| SCHEMBL18113024 | 0.80 | MAPK1 (0.54) | MAPK1MAPKAPK2GSK3BTGFBR1ACVR1 | |
| SCHEMBL18112932 | 0.79 | KCNH2 (0.55) | MAPK1 | |
| SCHEMBL22209338 | 0.79 | MAPK1 (0.50) | MAPK1GRM5MAPKAPK2GSK3BPARP10 | |
| SCHEMBL18113043 | 0.78 | MAPK1 (0.49) | MAPK1MAPKAPK2GSK3BPARP10PARP11 | |
| SCHEMBL18112995 | 0.78 | MAPK1 (0.49) | MAPK1GRM5MAPKAPK2PARP10PARP11 | |
| SCHEMBL22209337 | 0.78 | MAPK1 (0.59) | MAPK1MAPKAPK2GSK3BTGFBR1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710978-B2 | STK4 inhibitors for treatment of hematologic malignancies | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2018-04-26 | — | — | US | disclosed |
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | FONDAZIONE CENTRO SAN RAFFAELE (IT) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111916-A1 | STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES | STK4, STK3, STK11 | MAPK1 341/4885GRM5 1520/4885MAPKAPK2 90/4885 |
| US-10710978-B2 | STK4 inhibitors for treatment of hematologic malignancies | STK4, STK3, STK11 | MAPK1 341/4885GRM5 1520/4885MAPKAPK2 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.